Dr. Ulrich Dauer
Chief Executive Officer
4SC Resminostat – a novel epigenetic therapy to treat solid cancers in advanced clinical development
Resminostat, recently met the primary endpoint in a Phase II study in advanced liver cancer. The therapy mediates tumour cell “resensitisation” with a novel epigenetic mode of action. Resensitisation can suppress or reverse drug tolerance mechanisms that tumour cells can develop against cancer drugs. The supplementary administration of resminostat can enable the effective treatment of patients with cancer drugs to which patient response is no longer adequate.